Esther van Twuijver

5PUBLICATIONS
0CO-AUTHORS
Innate immunityPreventative health careNanotoxicology, health and safety
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 05, 2026
Heterologous prime-boost vaccination against H5 avian influenza: Safety and immunogenicity of a MF59-adjuvanted, cell-culture derived H5N6 vaccine.

|May 07, 2025
Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and Without Underlying Immunosuppressive Conditions.

Peter Malfertheiner, Eve Versage, Esther Van Twuijver

|May 25, 2024
Safety, Tolerability, and Immunogenicity of aH5N1 Vaccine in Adults with and without Underlying Medical Conditions.

Tomas Jelinek, Tino F Schwarz, Emil Reisinger

|Apr 23, 2022
Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects.

James Peterson, Esther Van Twuijver, Eve Versage

|Dec 28, 2021
Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults.

Eve Versage, Esther van Twuijver, Wim Jansen

Pageof 1

Frequent Collaborators